title: Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.
abstract: OBJECTIVE
  To improve the results obtained by cystectomy alone and to determine the possibilities of conservative treatment in invasive bladder cancer, we designed a prospective study using a combination of fluorouracil (5-FU) plus cisplatin and concomitant radiation therapy, followed by either cystectomy or additional chemoradiotherapy.
  
  
  METHODS
  Fifty-four patients with stage T2 to T4 operable untreated invasive bladder cancer were entered onto the study. Treatment was begun in all patients by transurethral resection (TUR) and followed by the 5-FU-cisplatin combination with concomitant bifractionated split-course radiation therapy. A control cystoscopy was performed 6 weeks after completion of the neoadjuvant program. Patients with persistent tumor underwent cystectomy. Complete responders were treated by either additional chemoradiotherapy (group A) or cystectomy (group B).
  
  
  RESULTS
  At control cystoscopy, 40 of 54 patients (74%) had a histologically documented complete response. Four responders developed recurrent pelvic disease after a mean follow-up time of 27 +/- 12 months (three in group A and one in group B). Metastatic disease, which developed in 16 patients, occurred more frequently in the nonresponders (71%) than in responders (15%). The disease-free survival rate at 3 years was 62%; it was significantly better in responders (77%) than in nonresponders (23%). There was no difference in survival between groups A and B.
  
  
  CONCLUSIONS
  This neoadjuvant chemoradiotherapy combination, easy to implement and well tolerated even in elderly patients, provides a high complete response rate. It may prove to be effective in inoperable patients and may be proposed as conservative treatment in patients with a complete response to the initial course of chemoradiation.
authors.affiliation: Service d'Oncologie-Radiothérapie, Hôpital Necker, Université Paris V, France.
authors.forename: M
authors.initials: M
authors.lastname: Housset
authors.forename: C
authors.initials: C
authors.lastname: Maulard
authors.forename: Y
authors.initials: Y
authors.lastname: Chretien
authors.forename: B
authors.initials: B
authors.lastname: Dufour
authors.forename: S
authors.initials: S
authors.lastname: Delanian
authors.forename: J
authors.initials: J
authors.lastname: Huart
authors.forename: F
authors.initials: F
authors.lastname: Colardelle
authors.forename: P
authors.initials: P
authors.lastname: Brunel
authors.forename: F
authors.initials: F
authors.lastname: Baillet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015653:Cystectomy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D002945:Cisplatin; D005472:Fluorouracil